Patent ID: 8440177

Claim:
A method of reducing severity or treating graft-versus-host disease (GVHD) in a mammal given a bone marrow transplant (BMT), the method comprising administering a pharmaceutical composition to the mammal given the BMT, wherein the pharmaceutical composition comprises: i) a therapeutically or prophylactically effective amount of an adipose derived mesenchymal stem cell (AD-MSC) population that is: (a) negative for CD3, CD11 b, CD14, CD19, CD31, CD34, CD45, CD62L, CD95L, CD117, and HLA-DR cell surface markers, and (b) positive for CD13, CD29, CD44, CD49e, CD73, CD90, CD105, CD166, and HLA-ABC cell surface markers, and ii) a pharmaceutically acceptable vehicle.